- Home
- IPW vs NXTC Comparison
IPW vs NXTC Comparison
Compare IPW & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPW
- NXTC
- Stock Information
- Founded
- IPW 2018
- NXTC 2015
- Country
- IPW United States
- NXTC United States
- Employees
- IPW N/A
- NXTC N/A
- Industry
- IPW Catalog/Specialty Distribution
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- IPW Consumer Discretionary
- NXTC Health Care
- Exchange
- IPW Nasdaq
- NXTC Nasdaq
- Market Cap
- IPW 14.4M
- NXTC 13.9M
- IPO Year
- IPW 2021
- NXTC 2019
- Fundamental
- Price
- IPW $0.66
- NXTC $6.17
- Analyst Decision
- IPW
- NXTC Strong Buy
- Analyst Count
- IPW 0
- NXTC 3
- Target Price
- IPW N/A
- NXTC $33.00
- AVG Volume (30 Days)
- IPW 189.7K
- NXTC 306.6K
- Earning Date
- IPW 09-18-2025
- NXTC 08-04-2025
- Dividend Yield
- IPW N/A
- NXTC N/A
- EPS Growth
- IPW N/A
- NXTC N/A
- EPS
- IPW N/A
- NXTC N/A
- Revenue
- IPW $74,105,251.00
- NXTC N/A
- Revenue This Year
- IPW $8.31
- NXTC N/A
- Revenue Next Year
- IPW $77.15
- NXTC N/A
- P/E Ratio
- IPW N/A
- NXTC N/A
- Revenue Growth
- IPW N/A
- NXTC N/A
- 52 Week Low
- IPW $0.41
- NXTC $2.69
- 52 Week High
- IPW $2.36
- NXTC $20.76
- Technical
- Relative Strength Index (RSI)
- IPW 51.56
- NXTC 62.21
- Support Level
- IPW $0.61
- NXTC $4.75
- Resistance Level
- IPW $0.72
- NXTC $5.23
- Average True Range (ATR)
- IPW 0.05
- NXTC 0.56
- MACD
- IPW -0.01
- NXTC 0.10
- Stochastic Oscillator
- IPW 28.31
- NXTC 86.74
About IPW iPower Inc.
iPower Inc is online hydroponic equipment and accessory retailer and supplier in North America. The company sells products through own website as well as online channel partners that include Amazon, Walmart, and eBay.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.